3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
5
Carcinoma, Ovarian Epithelial
4
Peritoneal Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma
2
Neoplasms, Glandular and Epithelial
1
Neoplasms
1
EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)
1
Ascites
1
Adenocarcinoma
1
Interventions
pembrolizumab
5
Cisplatin
4
Paclitaxel
3
lenvatinib
2
Fluorouracil
2
trastuzumab deruxtecan
1
sargramostim
1
resiquimod
1
poly ICLC
1
oregovomab
1
liposomal doxorubicin
1
fluoroazomycin arabinoside
1
fludarabine
1
cemiplimab
1
catumaxomab
1
cabozantinib
1
Therapeutics
1
Therapeutic Irrigation
1
TKM-080301
1
Radiation, Ionizing
1
Radiation
1
Quality of Life
1
Proctoscopy
1
Prednisone
1
Prednisolone
1
Patient Reported Outcome Measures
1
Papanicolaou Test
1
Oxaliplatin
1
Nelfinavir
1
Molecular Diagnostic Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
catumaxomab
×
Gynecologic
×
Clear all
NCT01504256
2018-01-23
CatuNeo
AIO-Studien-gGmbH
Phase 2
Completed
42 enrolled